Evidence map›Paper›PMID 34780064›Full record

ArticleEuropean journal of clinical investigation2022

Multiparametric analysis of coronary flow in psoriasis using a coronary flow reserve companion.

Francesco Tona, Elena Osto, Peter L M Kerkhof, Roberta Montisci, Giulia Famoso, Giulia Lorenzoni, Laura De Michieli, Annagrazia Cecere, Irene Zanetti, Giovanni Civieri and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Francesco TonaDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0003-4828-7875
Elena OstoUniversity Heart Center, University Hospital Zurich & University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-8196-5696
Peter L M KerkhofAmsterdam University Medical Centers, VUmc, Radiology and Nuclear Medicine, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9488-633X
Roberta MontisciClinical Cardiology, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Giulia FamosoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Giulia LorenzoniDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Laura De MichieliDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Annagrazia CecereDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Irene ZanettiDermatology Unit, Department of Medicine, University of Padova, Padova, Italy.
Giovanni CivieriDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Sabino IlicetoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Stefano PiasericoDermatology Unit, Department of Medicine, University of Padova, Padova, Italy.
University of Padua · ITAmsterdam University Medical Centers · NLUniversity of Cagliari · ITUniversity of Zurich · CH

Funding

Swiss Card-Onco-Grant (Alfred and Annemarie von Sick Grant)Swiss Heart Foundation FF19111Swiss National Science Foundation PRIMA Grant PR00P3_179861/1
6 · The paper itself

Abstract

backgroundCoronary microvascular dysfunction (CMD) is usually evaluated measuring coronary flow velocity reserve (CFVR). A more comprehensive analysis of CFVR including additional consideration of the associated logical companion-CFVR, where hyperemic diastolic coronary flow velocity may act as surrogate, was applied in this study to elucidate the mechanism of CMD in psoriasis. METHODS AND

resultsCoronary flow velocity reserve was analysed using transthoracic echocardiographs of 127 psoriasis patients (age 36 ± 8 years; 104 males) and of 52 sex- and age-matched healthy controls. CFVR determination was repeated in the patient subgroup (n = 78) receiving anti-inflammatory therapy. Baseline and hyperemic microvascular resistance (MR) were calculated. CMD was defined as CFVR ≤ 2.5. Four endotypes of CMD were identified referring to concordant or discordant impairments of hyperemic flow or CFVR. We evaluated the companion-CFVR, as derived from the quadratic mean of hyperemic and diastolic flow velocity at rest. Coronary flow parameters, including CFVR (p = 0.01), were different among the two endotypes having CFVR > 2.5. Specifically, all 11 (14%) patients with CFVR deterioration despite therapy, belonged to endotype 1, and had higher baseline and hyperemic MR (p < 0.0001, both). Interestingly, while CFVR was comparable in patients with worsened versus those with improved CFVR, the companion-CFVR could discriminate by being lower in patients with worsened CFVR (p = 0.01).

conclusionsThe reduced CFVR in psoriasis is driven by decreased companion-CFVR, combined with increased hyperemic MR. Adoption of the mandatory companion-CFVR enables a personalized characterization superior to that achieved by exclusive consideration of CFVR.

Indexed as

Coronary CirculationAdultCross-Sectional StudiesFemaleHumansMalePsoriasisanti-inflammatory therapycoronary flow reservecoronary microcirculationcoronary microvascular dysfunctionDoppler echocardiographypsoriasis

Identifiers

PMID34780064
PMCPMC9286413
OpenAlexW3211940155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.